The Genetics of Alzheimer Disease
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Family history is the second strongest risk factor for Alzheimer disease (AD) following advanced age.Twin and family studies indicate that genetic factors are estimated to play a role in at least 80% of AD cases.The inheritance of AD exhibits a dichotomous pattern.On one hand, rare mutations in APP, PSEN1, and PSEN2 virtually guarantee early-onset (,60 years) familial AD, which represents 5% of AD.On the other hand, common gene polymorphisms, such as the 14 and 12 variants of the APOE gene, can influence susceptibility for 50% of the common late-onset AD.These four genes account for 30% -50% of the inheritability of AD.Genome-wide association studies have recently led to the identification of 11 additional AD candidate genes.This paper reviews the past, present, and future attempts to elucidate the complex and heterogeneous genetic underpinnings of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“To date, 228 PSEN1 mutations have been identified causing ADAD (49, 303, 304, 440, 566, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“CLU gene encodes clusterin or APOJ that besides its functions in lipid transport, membrane recycling, cell adhesion, and apoptosis (90, 444, 600, 677) affects transvascular A 𝛃 clearance by promoting A 𝛃 42 efflux across the BBB (580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PSEN1 mutations lead to faster soluble-to-fibrillar conversion of A 𝛃 42 promoting amyloid deposition in the brain (303, 566, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Autosomal-dominant AD (ADAD) is an inherited form of AD caused by mutations in amyloid precursor protein ( APP ) and presenilin-1 and 2 ( PSEN1; PSEN2 ) genes (49, 177, 303, 304, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 is the major genetic risk factor for sporadic, late-onset AD (199, 368, 580, 612).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 3×
“Goate et al. (1991), then resequenced the same two APP exons to reveal the first EO-FAD mutation (London mutation; V717I) in APP.”
BackgroundThe precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619 · cited 1×
“In 1987, we as well as others isolated the amyloid b (A4) protein precursor (APP; Goldgaber et al. 1987; Kang et al. 1987; Tanzi et al. 1987a, 1988) and mapped it to chromosome 21.”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 3×
“1987b); they were ultimately demonstrated to carry PSEN1 mutations (Sherrington et al. 1995).”
BackgroundSelf-citationHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 14×
“Genetic association studies remain the most common method for identifying novel LOAD genes and are most often employed in the form of large-scale GWASs that screen the entire human genome for novel disease loci.”
InfluentialScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · cited 3×
“Whether EO-FAD mutations appear in APP near the g-secretase cleavage site or in the presenilins, the vast majority of them serve to increase the ratio of Ab42:Ab40. g-Secretase modulators are aimed at reversing this ratio and represent very promising compounds for treating and preventing AD based on what has been garn…”
BackgroundSelf-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · cited 1×
“Shortly thereafter, we first reported a homolog of PSEN1 called presenilin (PSEN2; Levy-Lahad et al. 1995) on chromosome 1 and showed that it harbors the N141I mutation in Volga-German EO-FAD families.”
BackgroundSelf-citationGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Research works printed but not linked: 2
- Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zis- mann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huen- telman MJ, et al. 2007. Papassotiropoulos A, Stephan DA. GAB2 alleles modify Alzheimer's risk in APOE 14 car- riers. Neuron 54: 713 -720.
- Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. 1993. Apolipopro- tein E: High-avidity binding to b-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci 90: 1977-1981.
Cited by
Items 201–300 of 804
Hofmann-Apitius, M., Ball, G., Gebel, S., Bagewadi, S., De Bono, B., Schneider, R., Page, M., Kodamullil, A., Younesi, E., Ebeling, C., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226148 · Cited by 55
The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes
Kepp, K. P., Sensi, S. L., Johnsen, K. B., Barrio, J. R., Høilund-Carlsen, P. F., Neve, R. L., Alavi, A., Herrup, K., Perry, G., Robakis, N. K., et al. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-230099 · Cited by 53
Genetics of Alzheimer’s Disease: the Importance of Polygenic and Epistatic Components
Raghavan, N., & Tosto, G. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0787-1 · Cited by 56
Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease
Moussa, C. E.-H. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1369527 · Cited by 53
Paraoxonase Role in Human Neurodegenerative Diseases
Reichert, C. O., Levy, D., & Bydlowski, S. P. (2020) · Antioxidants · doi:10.3390/antiox10010011 · Cited by 57
The Link Between Matrix Metalloproteinases and Alzheimer’s Disease Pathophysiology
Radošinská, D., & Radošinská, J. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04315-0 · Cited by 56
Genetic Testing and Counseling in the Diagnosis and Management of Young-Onset Dementias
Goldman, J. S. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.01.008 · Cited by 55
Sharoar, M. G., Shi, Q., Ge, Y., He, W., Hu, X., Perry, G., Zhu, X., & Yan, R. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.181 · Cited by 50
Imaging Alzheimer's genetic risk using diffusion MRI: A systematic review
Harrison, J. R., Bhatia, S., Tan, Z. X., Mirza-Davies, A., Benkert, H., Tax, C. M. W., & Jones, D. K. (2020) · NeuroImage: Clinical · doi:10.1016/j.nicl.2020.102359 · Cited by 46
Sphingosine-1-Phosphate: Boon and Bane for the Brain
van Echten-Deckert, G., Hagen-Euteneuer, N., Karaca, I., & Walter, J. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000362991 · Cited by 50
Bignante, E. A., Heredia, F., Morfini, G. A., & Lorenzo, A. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.021 · Cited by 64
Copy Number Variants in Alzheimer’s Disease
Cuccaro, D., Marco, E. V. D., Cittadella, R., & Cavallaro, S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160469 · Cited by 55
Alzheimer’s Disease, Anesthesia, and Surgery: A Clinically Focused Review
Berger, M., Burke, J. R., Eckenhoff, R. G., & Mathew, J. P. (2014) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2014.04.014 · Cited by 53
Hall, A., & Patel, T. R. (2014) · Progress in medicinal chemistry · doi:10.1016/b978-0-444-63380-4.00003-2 · Cited by 51
Epitope‐based DNA vaccine for Alzheimer's disease: Translational study in macaques
Evans, C. F., Davtyan, H., Petrushina, I., Hovakimyan, A., Davtyan, A., Hannaman, D., Cribbs, D. H., Agadjanyan, M. G., & Ghochikyan, A. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.04.505 · Cited by 49
Substrate recognition and processing by γ-secretase
Wolfe, M. S. (2019) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2019.07.004 · Cited by 53
Xian, Y., Qu, C. F., Liu, Y., Ip, S., Yuan, Q., Yang, W., & Lin, Z. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5920476 · Cited by 52
Alzheimer’s Disease: Drug Discovery
(2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020 · Cited by 44
The role of genetic risk factors of Alzheimer’s disease in synaptic dysfunction
Fu, W.-Y., & Ip, N. Y. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.07.011 · Cited by 48
Fernandes, T., Domingues, M. R., Moreira, P. I., & Pereira, C. (2023) · Biology · doi:10.3390/biology12030414 · Cited by 51
Biophysical Comparison of Soluble Amyloid-β(1–42) Protofibrils, Oligomers, and Protofilaments
Nichols, M. R., Colvin, B. A., Hood, E. A., Paranjape, G. S., Osborn, D. C., & Terrill, S. E. (2015) · Biochemistry · doi:10.1021/bi500957g · Cited by 51
Nyarko, J. N. K., Quartey, M. O., Pennington, P. R., Heistad, R. M., Dea, D., Poirier, J., Baker, G. B., & Mousseau, D. D. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.01.005 · Cited by 41
Sharma, A., & Dey, P. (2021) · Genomics · doi:10.1016/j.ygeno.2021.04.028 · Cited by 53
Podvin, S., Jones, A., Liu, Q., Aulston, B., Ransom, L., Ames, J., Shen, G., Lietz, C. B., Jiang, Z., O'Donoghue, A. J., et al. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra120.002079 · Cited by 45
The fusiform gyrus exhibits an epigenetic signature for Alzheimer’s disease
Ma, D., Fetahu, I. S., Wang, M., Fang, R., Li, J., Liu, H., Gramyk, T., Iwanicki, I. J., Gu, S., Xu, W., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00916-3 · Cited by 52
Koklesová, L., Líšková, A., Samec, M., Zhai, K., AL-Ishaq, R. K., Bugos, O., Šudomová, M., Biringer, K., Péč, M. J., Adamkov, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168649 · Cited by 48
Surya, K., Manickam, N., Jayachandran, K. S., Kandasamy, M., & Anusuyadevi, M. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220559 · Cited by 49
Afsar, A., Castro, M. D. C. C., Soladogun, A. S., & Li, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087258 · Cited by 49
Mitochondrial DAMPs: Key mediators in neuroinflammation and neurodegenerative disease pathogenesis
Yu, H., Ren, K., Jin, Y., Zhang, L., Liu, H., Huang, Z., Zhang, Z., Chen, X., Yang, Y., & Wei, Z. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110217 · Cited by 51
Jakobsen, J. E., Johansen, M. G., Schmidt, M., Liu, Y., Li, R., Callesen, H., Melnikova, M., Habekost, M., Matrone, C., Bouter, Y., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160408 · Cited by 46
Contribution of astrocytes to metabolic dysfunction in the Alzheimer’s disease brain
Zulfiqar, S., Garg, P., & Nieweg, K. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0140 · Cited by 47
Reinert, J., Richard, B. C., Klafki, H. W., Friedrich, B., Bayer, T. A., Wiltfang, J., Kovacs, G. G., Ingelsson, M., Lannfelt, L., Paetau, A., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0294-7 · Cited by 44
Early and sustained altered expression of aging-related genes in young 3xTg-AD mice
Gatta, V, D'Aurora, M., Granzotto, A., Stuppia, L., & Sensi, S. L. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.11 · Cited by 44
Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease
Wirths, O., & Zampar, S. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1702972 · Cited by 44
Fagan, S. G., Béchet, S., & Dev, K. K. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02613-5 · Cited by 61
Amyloid Precursor Protein: A Regulatory Hub in Alzheimer's Disease
Chen, J., Chen, J.-S., Li, S., Zhang, F., Deng, J., Zeng, L., & Tan, J. (2023) · Aging and Disease · doi:10.14336/ad.2023.0308 · Cited by 62
Microbial signatures and therapeutic strategies in neurodegenerative diseases
Rob, M., Yousef, M., Lakshmanan, A. P., Mahboob, A., Terranegra, A., & Châari, A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117905 · Cited by 47
(ADNI), F. T. A. D. N. I., Nho, K., Kim, S., Horgusluoglu, E., Risacher, S. L., Shen, L., Kim, D., Lee, S., Foroud, T., Shaw, L. M., et al. (2017) · BMC Medical Genomics · doi:10.1186/s12920-017-0267-0 · Cited by 44
Hamilton, L. K., & Fernandes, K. J. L. (2017) · Biology of the Cell · doi:10.1111/boc.201700037 · Cited by 44
Dissecting Alzheimer disease in Down syndrome using mouse models
Choong, X. Y., Tosh, J. L., Pulford, L. J., & Fisher, E. M. C. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00268 · Cited by 42
McIntee, F. L., Giannoni, P., Blais, S., Sommer, G., Neubert, T. A., Rostagno, A., & Ghiso, J. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00223 · Cited by 42
Acute ACAT1/SOAT1 Blockade Increases MAM Cholesterol and Strengthens ER-Mitochondria Connectivity
Harned, T. C., Stan, R. V., Cao, Z., Chakrabarti, R., Higgs, H. N., Chang, C. C. Y., & Chang, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065525 · Cited by 48
Yarbro, J. M., Han, X., Dasgupta, A., Yang, K., Liu, D., Shrestha, H. K., Zaman, M., Wang, Z., Yu, K., Lee, D. G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56853-3 · Cited by 41
Kim, S., Sharma, C., Jung, U. J., & Kim, S. R. (2023) · Biomedicines · doi:10.3390/biomedicines11051383 · Cited by 43
Vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease
Galvan, V., & Hart, M. J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.11.010 · Cited by 40
Sathya, M., Moorthi, P., Premkumar, P., Kandasamy, M., Jayachandran, K. S., & Anusuyadevi, M. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161034 · Cited by 41
Zhu, M., Jia, L., Li, F., & Jia, J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00981 · Cited by 47
Tackenberg, C., Kulic, L., & Nitsch, R. M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239584 · Cited by 45
Mercan, D., & Heneka, M. T. (2022) · Biology · doi:10.3390/biology11121822 · Cited by 45
The role of CD56bright NK cells in neurodegenerative disorders
Rodriguez-Mogeda, C., van Ansenwoude, C. M. J., van der Molen, L. H., Strijbis, E. M. M., Mebius, R. E., & de Vries, H. E. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03040-8 · Cited by 43
Sadleir, K. R., Eimer, W. A., Kaufman, R. J., Osten, P., & Vassar, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101643 · Cited by 36
Immunotherapies in Alzheimer’s disease: Too much, too little, too late or off-target?
St‐Amour, I., Cicchetti, F., & Calon, F. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1518-9 · Cited by 42
The vexing complexity of the amyloidogenic pathway
Castro, M., Hadziselimovic, A., & Sanders, C. R. (2019) · Protein Science · doi:10.1002/pro.3606 · Cited by 44
Delivering pharmacogenetic testing in a primary care setting
Mills, R. A., Voora, D., Peyser, B., & Haga, S. B. (2013) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s50598 · Cited by 39
Richards, R. I., Robertson, S. A., O'Keefe, L. V., Fornarino, D., Scott, A., Lardelli, M., & Baune, B. T. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00193 · Cited by 36
The Role of HDL and HDL Mimetic Peptides as Potential Therapeutics for Alzheimer’s Disease
Chernick, D., Zhong, R., & Li, L. (2020) · Biomolecules · doi:10.3390/biom10091276 · Cited by 44
Progress in the genetic analysis of Parkinson’s disease
Singleton, A., & Hardy, J. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz179 · Cited by 40
Wang, J., Qin, X., Sun, H., He, M., Lv, Q., Gao, C., He, X., & Liao, H. (2021) · Aging Cell · doi:10.1111/acel.13515 · Cited by 39
Pandey, R. S., Graham, L., Uyar, A., Preuss, C., Howell, G. R., & Carter, G. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0351-3 · Cited by 37
Use of ocular biomarkers as a potential tool for early diagnosis of Alzheimer's disease
Singh, A., & Verma, S. (2020) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_999_19 · Cited by 39
Machine learning for the life-time risk prediction of Alzheimer’s disease: a systematic review
Rowe, T. W., Katzourou, I. K., Stevenson‐Hoare, J. O., Bracher‐Smith, M., Ivanov, D. K., & Escott‐Price, V. (2021) · Brain Communications · doi:10.1093/braincomms/fcab246 · Cited by 44
Integrated Approaches for Analyzing U1-70K Cleavage in Alzheimer’s Disease
Bai, B., Chen, P., Hales, C. M., Wu, Z., Pagala, V., High, A. A., Levey, A. I., Lah, J. J., & Peng, J. (2014) · Journal of Proteome Research · doi:10.1021/pr5003593 · Cited by 37
Hale, J. M. (2017) · Demography · doi:10.1007/s13524-017-0629-4 · Cited by 38
New Roles for Old Glue: Astrocyte Function in Synaptic Plasticity and Neurological Disorders
Hussaini, S. M. Q., & Jang, M. H. (2018) · International Neurourology Journal · doi:10.5213/inj.1836214.107 · Cited by 35
iPSCs: A Preclinical Drug Research Tool for Neurological Disorders
Bonaventura, G., Iemmolo, R., Attaguile, G. A., Cognata, V. L., Pistone, B. S., Raudino, G., D’Agata, V., Cantarella, G., Barcellona, M. L., & Cavallaro, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094596 · Cited by 36
Ramakrishna, S., Jhaveri, V., Konings, S. C., Nawalpuri, B., Chakraborty, S., Holst, B., Schmid, B., Gouras, G. K., Freude, K., & Muddashetty, R. S. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.0435-21.2021 · Cited by 37
AZP2006, a new promising treatment for Alzheimer’s and related diseases
Callizot, N., Estrella, C., Burlet, S., Henriques, A., Brantis, C., Barrier, M., Campanari, M. L., & Verwaerde, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-94708-1 · Cited by 35
Extracellular Proteolysis of Apolipoprotein E (apoE) by Secreted Serine Neuronal Protease
Tamboli, I. Y., Heo, D., & Rebeck, G. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093120 · Cited by 35
Protocol for fast screening of multi-target drug candidates: Application to Alzheimer’s disease
Thai, N. Q., Nguyen, H. L., Linh, H. Q., & Li, M. S. (2017) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2017.08.002 · Cited by 36
Gadhave, K., Gehi, B. R., Kumar, P., Xue, B., Uversky, V. N., & Giri, R. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03414-9 · Cited by 36
Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review
Vogrinc, D., Goričar, K., & Dolžan, V. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.646901 · Cited by 36
Exploring the Causal Relationship Between Telomere Biology and Alzheimer’s Disease
Kuan, X.-Y., Fauzi, N. S. A., Ng, K. Y., & Bakhtiar, A. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03337-4 · Cited by 38
Rodríguez‐Izquierdo, I., Serramía, M. J., Gómez, R., De La Mata, F. J., Bullido, M. J., & Muñoz‐Fernández, M. Á. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010155 · Cited by 37
Tournissac, M., Vu, T.-M., Vrabic, N., Hozer, C., Tremblay, C., Mélançon, K., Planel, E., Pifferi, F., & Calon, F. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00842-3 · Cited by 35
Bhole, R. P., Chikhale, R. V., & Rathi, K. M. (2023) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2023.11.003 · Cited by 37
Vassar, R. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.3 · Cited by 31
The Molecular Bases of Anti-Oxidative and Anti-Inflammatory Properties of Paraoxonase 1
Jakubowski, H. (2024) · Antioxidants · doi:10.3390/antiox13111292 · Cited by 36
Criscuolo, C., Fabiani, C., Cerri, E., & Domenici, L. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00053 · Cited by 36
Good Cop, Bad Cop: Defining the Roles of Δ40p53 in Cancer and Aging
Reinhardt, L. S., Zhang, X., Wawruszak, A., Groen, K., Iuliis, G. N. D., & Avery‐Kiejda, K. A. (2020) · Cancers · doi:10.3390/cancers12061659 · Cited by 37
Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 36
Kępka, A., Ochocińska, A., Borzym‐Κluczyk, M., Chojnowska, S., Skorupa, E., Przychodzeń, M., & Waszkiewicz, N. (2022) · Nutrients · doi:10.3390/nu14081534 · Cited by 37
Moya‐Alvarado, G., Guerra, M. V., Tiburcio, R., Bravo, E., & Bronfman, F. C. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105796 · Cited by 36
Miras-Portugal, M. T., Diaz-Hernandez, J. I., Gomez-Villafuertes, R., Diaz-Hernandez, M., Artalejo, A. R., & Gualix, J. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.02.005 · Cited by 34
ADAM10 Prodomain Mutations Cause Late-Onset Alzheimer’s Disease: Not Just the Latest FAD
Vassar, R. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.031 · Cited by 32
“APP duplication in trisomy 21 (Down syndrome) or rare duplications limited to small chromosomal regions that include the APP locus also cause EO-FAD by raising total Ab production via increased 250 Neuron 80, October 16, 2013 ª2013 Else APP dosage.”
BackgroundInfluentialViral Infections, Are They a Trigger and Risk Factor of Alzheimer’s Disease?
Rippee‐Brooks, M. D., Wu, W., Dong, J., Pappolla, M. A., Fang, X., & Bao, X. (2024) · Pathogens · doi:10.3390/pathogens13030240 · Cited by 32
Tau immunization: a cautionary tale?
Mably, A. J., Kanmert, D., Donald, J. M. M., Liu, W., Caldarone, B. J., Lemere, C. A., O’Nuallain, B., Kosik, K. S., & Walsh, D. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.11.022 · Cited by 33
Xiang, Q., Bi, R., Xu, M., Zhang, D., Tan, L., Zhang, C., Fang, Y., & Yao, Y. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0065-2 · Cited by 34
Microglia and its Genetics in Alzheimer's Disease
Liang, X., Wu, H., Colt, M., Guo, X., Pluimer, B. R., Zeng, J., Dong, S., & Zhao, Z. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211105140732 · Cited by 36
Structure and mechanism of the γ-secretase intramembrane protease complex
Wolfe, M. S., & Miao, Y. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102373 · Cited by 32
Ewald, C. Y., Marfil, V., & Li, C. (2016) · Aging Cell · doi:10.1111/acel.12509 · Cited by 32
Yoshikawa, M., Soeda, Y., Michikawa, M., Almeida, O. F. X., & Takashima, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00124 · Cited by 33
FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease
Yan, T., Liang, J., Gao, J., Wang, L., Fujioka, H., Initiative, T. A. D. N., Weiner, M. W., Schuff, N. W., Rosen, H. J., Miller, B. L., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13962-0 · Cited by 32
Christodoulou, C. C., Pitsillides, M., Hadjisavvas, A., & Zamba‐Papanicolaou, E. (2025) · Nutrients · doi:10.3390/nu17020336 · Cited by 31
VPS13D interacts with VCP/p97 and negatively regulates ER- mitochondrial interactions
Du, Y., Wang, J., Xiong, J., Fang, N., & Ji, W.-K. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e21-03-0097 · Cited by 32
Role of astrocytic glycolytic metabolism in Alzheimer’s disease pathogenesis
Fu, W., & Jhamandas, J. H. (2014) · Biogerontology · doi:10.1007/s10522-014-9525-0 · Cited by 39
Alzheimer’s in a dish – induced pluripotent stem cell-based disease modeling
de Leeuw, S., & Tackenberg, C. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0161-0 · Cited by 31
Sattarov, R., Havers, M., Orbjörn, C., Stomrud, E., Janelidze, S., Laurell, T., & Mattsson, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-75406-0 · Cited by 33
Toward common mechanisms for risk factors in Alzheimer's syndrome
Medina, M., Khachaturian, Z. S., Rossor, M., Avila, J., & Cedazo‐Minguez, A. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.08.009 · Cited by 29
Oncogenic Pathways in Neurodegenerative Diseases
Varela, L., & García-Rendueles, M. E. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063223 · Cited by 31
Mechanism of Tripeptide Trimming of Amyloid β-Peptide 49 by γ-Secretase
Bhattarai, A., Devkota, S., Do, H. N., Wang, J., Bhattarai, S., Wolfe, M. S., & Miao, Y. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c10533 · Cited by 33
Metadata
- Authors
- Tanzi, R. E.
- Affiliations
- Harvard University (US)
- Corresponding author
- Tanzi, R. E.
- ORCID
- Tanzi, R. E.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-07-25
- Volume
- 2
- Issue
- 10
- Pages
- a006296-a006296
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W4233829850
- Cited by
- 727
- References
- 55
- Citations by year
- 2026: 40 · 2025: 55 · 2024: 58 · 2023: 70 · 2022: 54 · 2021: 49 · 2020: 54 · 2019: 40 · 2018: 42 · 2017: 55 · 2016: 60 · 2015: 52 · 2014: 61 · 2013: 32 · 2012: 5
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, genetic susceptibility, familial Alzheimer's disease, APP mutations, presenilin 1, presenilin 2, apolipoprotein E, APOE ε4, late-onset Alzheimer's disease, twin and family studies, genome-wide association study, candidate genes, heritability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.